Genscript Chairman Joins Board of Nasdaq-Listed Associate Legend Biotech
I'm PortAI, I can summarize articles.
Genscript Biotech has announced that its chairman, Jiange (Robin) Meng, will join the board of its associate company, Legend Biotech Corporation, effective January 20, 2026. This appointment aims to strengthen ties between the two companies and enhance strategic coordination. Investors are advised to be cautious, as the latest analyst rating for Genscript's stock is a Sell, with a price target of HK$13.00. Genscript Biotech is a Hong Kong-listed life sciences company with a strategic interest in Legend Biotech, which is listed on Nasdaq.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments